Sagent Pharmaceuticals

Sagent Pharmaceuticals
Public
Traded as NASDAQ: SGNT
Industry Biotechnology
Key people

Allan Oberman (CEO)[1]

Jonathon Singer (CFO)
Revenue $318 million
$23 million
Website sagentpharma.com

Sagent Pharmaceuticals is a biopharmaceutical company founded in 2007. The company received series A funding of $53 million,[2] as well as $40 million in two rounds of series B funding.[3] As part of the funding, Zhejiang Hisun Pharmaceutical Co. Ltd made an investment of $10 million in Sagent. In total, the company has raised $153 million in equity capital.[3] In 2011 the company filed for IPO - offering 5,750,000 shares of common stock at a price to the public of $16 per share[4]

The company was acquired by Nichi-Iko Pharmaceutical Co., Ltd in 2016.

Company history

In 2010, the company entered a partnership with Actavis to market and supply a number of injectable products.[5]

In 2014, the company announced its intention to acquire Omega Laboratories Limited for $85.3 million[6]

In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.[7]

In 2016, the company made its most notable acquisition to date, when it acquired five Abbreviated New Drug Applications from Teva Pharmaceuticals for $40 million. As part of Teva's acquisition on Actavis Generics, a number of drug portfolios are being sold off.[8] Later in the same year, the company was acquired by Nichi-Iko Pharmaceutical Co., Ltd for $736 million[9][10] (representing $21.75 per share and a 40% share premium).[11][12][13]

References

This article is issued from Wikipedia - version of the 9/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.